• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/23

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

23 Cards in this Set

  • Front
  • Back
The action of heparin can be reversed by treatment with
administration of antagonist, protamine sulfate
MOA for Heparin
increase by 1000X fold antithrombin activity
Factors inhibited by antithrombin
II, Ix, X
Heparin contra-indication
HIT, active bleeding, hemophilia
Administration of Heparin
Only IV or Subcutaneous
Why is heparin not administered IM?
avoid risk of hematoma
LMW heparin (aka fractionated heparin)

better bioavailability
more selective
dose less frequently
Enoxaprin
Drug of choice for anticoagulants in pregnancy
Heparin does not cross placental barrier
How to treat Heparin-induced thrombocytopenia?
Fondaparinux
Direct Thrombin Inhibitors
Desirudin and Bivalirudin and Leparudin
Argatroban and Melagatran
Vitamin K dependent factors
VII, IX, X, II (thrombin), Protein C, Protein S
Metabolism of coumarin
Cyt P450- Liver
Thrombolytics
t-PA
Streptokinase
Urokinase
t-PA
Alteplase, Reteplase, Tenecteplase
Glycoprotein IIb/IIIa receptor
binds fibrinogen
antiplatelet-action to glycoproteinn IIb/IIIa receptor
abciximab
eptifibatide
tirofiban
platelet aggregationn promoting factors
ADP
TXA2
5-HT Serotonin
PDE (phosphodiesterase 3) inhibitors
dipyridamole, cilostazol
Antiplasmin Agents
Aminocaproic Acid
Tranexamic Acid
Desmopressin
vaspressinn V2 receptor agonist
Aprotinin
serine protease inhibitor
inhibits fibrinolysis by plasmin and by plasmin streptokinase complex
MOA of ASA and NSAIDS
inhibit thomboxane synthesis by blocking the enzyme cyclooxygenase
MOA of clopidogrel and ticlopidine
irreversible inhibition of ADP mediated platelet aggregation